Miraculins Inc (MCUIF) 0.1550 $MCUIF
Miraculins Completes Share Consolidation
Marketwire - Fri Jan 24, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares" on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent.
Miraculins Releases CEO Letter to Shareholders
Marketwire - Mon Jan 20, 6:19AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today issues the following letter to shareholders from Company President & CEO Christopher Moreau:
Miraculins Announces First Closing of Private Placement Offering
Marketwire - Fri Sep 20, 4:06PM CDT
Miraculins Inc. (TSX VENTURE: MOM), (the "Company" , a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce the first close of a private placement offering (the "Offering" with aggregate gross proceeds to the Company of $430,000 from the sale of 7,166,667 units ("Units" at a price of $0.06 per Unit. Each Unit is comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant (a "Warrant" .
Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening Test to be Piloted by Major Canadian Supermarket Chain
Marketwire - Mon Sep 16, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that a major Canadian supermarket chain, in collaboration with Pear Healthcare Solutions ("Pear" , a leading provider of in-pharmacy health screening and educational services to the Canadian pharmacy community, will be conducting a special pilot of the Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening technology as part of a series of pharmacy diabetes clinics to be held at 35 store locations in fall 2013.
Miraculins Announces Private Placement Offering
Marketwire - Thu Sep 12, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces a non-brokered private placement offering (the "Offering" of up to 16,666,666 units ("Units" at a price of $0.06 per Unit for gross proceeds of up to $1,000,000. Each Unit will be comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant. Each whole warrant (a "Warrant" will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 12 months from the date the Warrant is issued.
Miraculins Announces Publication of Comprehensive Review Article on Skin Cholesterol and Its Link to Increased Cardiovascular Risk
Marketwire - Mon Sep 09, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today the publication of a review article entitled "The Relationship Between Skin Cholesterol Testing and Parameters of Cardiovascular Risk: A Systematic Review" authored by A. Yashar Tashakkor, MD, and G. B. John Mancini, MD, FRCPC of the Department of Medicine (Division of Cardiology), University of British Columbia.
Miraculins Announces H-E-B Store Locations for Its PreVu(R) Skin Cholesterol Test Pilot in Texas
Marketwire - Thu Sep 05, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" , a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today the 20 store locations where H-E-B, the #1 food retailer in South and Central Texas and the State's largest private company, will be conducting a pilot launch of the Company's PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test this fall. This is the first such launch of the product into the United States.
Miraculins Announces Issuance of Independent Analyst's Research Report from New York Based RB Milestone Group
Marketwire - Thu Aug 22, 1:35PM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today that an independent analyst's research report has been issued by New York based RB Milestone Group, LLC ("RB Milestone" .
Miraculins Highlights New Peer-Reviewed Publications on SCOUT DS(R)
Marketwire - Mon Aug 19, 5:31AM CDT
Editors note: There is one photo associated with this press release.
Miraculins Re-Appoints Pear Healthcare Solutions to Distribute Scout DS(R) to Canadian Retail Pharmacy/Grocery Market
Marketwire - Fri Aug 16, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today that it has re-appointed Pear Healthcare Solutions Inc. ("Pear" , a leading provider of in-pharmacy health screening and education services, as the distributor for the SCOUT DS(R) Non-Invasive Diabetes Test Technology to the Canadian retail pharmacy/grocery market. Pear is also the Company's Canadian distributor for the PreVu(R) Non-Invasive Skin Cholesterol Point-of-Care (POC) Test to the same market segment.
Miraculins Completes Share Consolidation
Marketwire - Fri Jan 24, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares" on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent. Miraculins Releases CEO Letter to Shareholders
Marketwire - Mon Jan 20, 6:19AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today issues the following letter to shareholders from Company President & CEO Christopher Moreau: Miraculins Announces First Closing of Private Placement Offering
Marketwire - Fri Sep 20, 4:06PM CDT
Miraculins Inc. (TSX VENTURE: MOM), (the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce the first close of a private placement offering (the "Offering" with aggregate gross proceeds to the Company of $430,000 from the sale of 7,166,667 units ("Units" at a price of $0.06 per Unit. Each Unit is comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant (a "Warrant" . Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening Test to be Piloted by Major Canadian Supermarket Chain
Marketwire - Mon Sep 16, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that a major Canadian supermarket chain, in collaboration with Pear Healthcare Solutions ("Pear" , a leading provider of in-pharmacy health screening and educational services to the Canadian pharmacy community, will be conducting a special pilot of the Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening technology as part of a series of pharmacy diabetes clinics to be held at 35 store locations in fall 2013. Miraculins Announces Private Placement Offering
Marketwire - Thu Sep 12, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces a non-brokered private placement offering (the "Offering" of up to 16,666,666 units ("Units" at a price of $0.06 per Unit for gross proceeds of up to $1,000,000. Each Unit will be comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant. Each whole warrant (a "Warrant" will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 12 months from the date the Warrant is issued. Miraculins Announces Publication of Comprehensive Review Article on Skin Cholesterol and Its Link to Increased Cardiovascular Risk
Marketwire - Mon Sep 09, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today the publication of a review article entitled "The Relationship Between Skin Cholesterol Testing and Parameters of Cardiovascular Risk: A Systematic Review" authored by A. Yashar Tashakkor, MD, and G. B. John Mancini, MD, FRCPC of the Department of Medicine (Division of Cardiology), University of British Columbia. Miraculins Announces H-E-B Store Locations for Its PreVu(R) Skin Cholesterol Test Pilot in Texas
Marketwire - Thu Sep 05, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today the 20 store locations where H-E-B, the #1 food retailer in South and Central Texas and the State's largest private company, will be conducting a pilot launch of the Company's PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test this fall. This is the first such launch of the product into the United States. Miraculins Announces Issuance of Independent Analyst's Research Report from New York Based RB Milestone Group
Marketwire - Thu Aug 22, 1:35PM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today that an independent analyst's research report has been issued by New York based RB Milestone Group, LLC ("RB Milestone" . Miraculins Highlights New Peer-Reviewed Publications on SCOUT DS(R)
Marketwire - Mon Aug 19, 5:31AM CDT
Editors note: There is one photo associated with this press release.
Miraculins Re-Appoints Pear Healthcare Solutions to Distribute Scout DS(R) to Canadian Retail Pharmacy/Grocery Market
Marketwire - Fri Aug 16, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today that it has re-appointed Pear Healthcare Solutions Inc. ("Pear" , a leading provider of in-pharmacy health screening and education services, as the distributor for the SCOUT DS(R) Non-Invasive Diabetes Test Technology to the Canadian retail pharmacy/grocery market. Pear is also the Company's Canadian distributor for the PreVu(R) Non-Invasive Skin Cholesterol Point-of-Care (POC) Test to the same market segment. 
